Figure 3.

mCBSC-dEXOs decrease activation of profibrotic genes in murine adult aortic fibroblasts (MAAFs). A–D: qPCR quantification of MAAFs fibroblasts following 72 h treatment with base growth medium, MAAF-CM, mCBSC-CM, and mCBSC-dEXOs (2.5 × 10⁸ particles/cell treated). All data are normalized to GAPDH. A: mCBSC exosome treatment leads to 0.5-fold decrease in Col1A1 expression in murine endothelial fibroblasts (MEF). B: Col3A1 is reduced by 0.5 fold by MEF-CM treatment, to 0.25 fold by mCBSC-CM treatment, and to 0.20 fold by mCBSC exosome treatment. C: MMP2 is increased in MAAFs treatment with MAAF CM, but remains consistent between the base growth medium and the mCBSC-CM and mCBSC-dEXO treatments. D: VEGFA is increased in the MAAF-CM-treated MAAFs but remains unchanged in the MAAFs following mCBSC-CM and mCBSC-dEXO treatment (base growth medium: n = 2; MAAF-CM: n = 3; mCBSC-CM: n = 3; mCBSC-dEXO: n = 3; one-sample t tests were performed). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. CBSCs, cortical bone stem cells; MAAF-CM, MAAF conditioned medium; mCBSC, mouse CBSCs; mCBSC-CM, mCBSC conditioned medium; mCBSC-dEXO, mouse CBSC-derived exosomes; MMP2, Matrix metalloproteinase 2.